[1]张 健.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效及对炎性因子、免疫球蛋白水平的影响[J].医学信息官方网站,2022,35(15):107-109.[doi:10.3969/j.issn.1006-1959.2022.15.024]
 ZHANG Jian.Effect of Montelukast Sodium Combined with Loratadine in the Treatment of Anaphylactoid Purpura in Children and its Effect on Inflammatory Factors and Immunoglobulin Levels[J].Medical Information,2022,35(15):107-109.[doi:10.3969/j.issn.1006-1959.2022.15.024]
点击复制

孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效及对炎性因子、免疫球蛋白水平的影响()
分享到:

《医学信息》官方网站[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年15期
页码:
107-109
栏目:
论著
出版日期:
2022-08-01

文章信息/Info

Title:
Effect of Montelukast Sodium Combined with Loratadine in the Treatment of Anaphylactoid Purpura in Children and its Effect on Inflammatory Factors and Immunoglobulin Levels
文章编号:
1006-1959(2022)15-0107-03
作者:
张 健
(蓟州区人民医院感染管理部,天津 301900)
Author(s):
ZHANG Jian
(Department of Infection management,Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
过敏性紫癜孟鲁司特钠氯雷他定炎性因子免疫球蛋白
Keywords:
Anaphylactoid purpuraMontelukast sodiumLoratadineInflammatory factorsImmunoglobulin
分类号:
R554+.6
DOI:
10.3969/j.issn.1006-1959.2022.15.024
文献标志码:
A
摘要:
目的 探究孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜(AP)的疗效及对炎性因子及免疫球蛋白水平的影响。方法 选取2019年6月-2021年6月我院收治的64例AP患儿为研究对象,采用随机数字表法分为对照组与观察组,各32例。对照组采用氯雷他定治疗,观察组在对照组基础上联合孟鲁司特钠治疗,比较两组临床疗效、症状消失时间、炎性因子水平(IL-6、IL-10、TNF-α)、免疫球蛋白水平(IgE、IgA)及不良反应发生情况。结果 观察组治疗总有效率为87.50%,高于对照组的71.88%(P<0.05);观察组皮肤症状、消化道症状、关节症状、肾脏症状消退时间均短于对照组(P<0.05);观察组IL-6、IL-10、TNF-α、IgE、IgA水平低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 孟鲁司特钠联合氯雷他定治疗AP患儿的疗效确切,可缩短症状消退时间,下调炎性因子水平,缓解过敏反应,且安全性较高。
Abstract:
Objective To explore the efficacy of montelukast sodium combined with loratadine in the treatment of pediatric anaphylactoid purpura (AP) and its influence on inflammatory factors and immunoglobulin levels.Methods A total of 64 children with AP admitted to our hospital from June 2019 to June 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 32 cases in each group. The control group was treated with loratadine, and the observation group was treated with montelukast sodium on the basis of the control group. The clinical efficacy, symptom disappearance time, inflammatory factor levels (IL-6, IL-10, TNF-α), immunoglobulin levels (IgE, IgA) and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 87.50 %, which was higher than 71.88 % of the control group (P<0.05). The regression time of skin symptoms, digestive tract symptoms, joint symptoms and kidney symptoms in the observation group were shorter than those in the control group (P<0.05). The levels of IL-6, IL-10, TNF-α, IgE and IgA in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Montelukast sodium combined with loratadine is effective in the treatment of children with AP, which can shorten the time of symptom extinction, reduce the level of inflammatory factors, alleviate allergic reactions, and has high safety.

参考文献/References:

[1]陈谊.孟鲁司特钠联合复方甘草酸苷对小儿过敏性紫癜的临床疗效及对免疫指标的影响[J].吉林医学,2021,42(8):1934-1936.[2]Lei WT,Tsai PL,Chu SH,et al.Incidence and risk factors for recurrent Henoch-Sch?觟nlein purpura in children from a 16-year nationwide database[J].Pediatr Rheumatol Online J,2018,16(1):25.[3]何丽芬,谢丹,李琳红,等.孟鲁司特钠对小儿反复发作性过敏性紫癜的治疗疗效研究[J].辽宁医学杂志,2021,35(2):14-16.[4]王翠.孟鲁司特钠联合氯雷他定及西咪替丁治疗反复发作过敏性紫癜患儿的疗效观察[J].现代诊断与治疗,2019,30(24):4347-4349.[5]宋艳,张炜灵,杜丽琴.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜疗效观察[J].海南医学,2020,31(16):2096-2098.[6]胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2002:678-690.[7]江溪.孟鲁司特联合氯雷他定对过敏性紫癜患儿血清TNF-α、IL-6及OPN水平的影响[J]. 河南大学学报(医学版),2018,37(3):179-181.[8]凌振球.孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的临床效果分析[J].中外医学研究,2018,16(17):150-152.[9]黄丽霞.孟鲁司特钠联合氯雷他定治疗反复发作性过敏性紫癜患儿的疗效观察[J].皮肤病与性病,2019,41(4):568-569.[10]卢素敏,张桂聪,龙丽娜.氯雷他定联合甲基强的松治疗小儿过敏性紫癜的临床效果分析[J].哈尔滨医药,2021,41(3):31-32.[11]陈赛琴.评估孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的疗效与安全性[J].现代诊断与治疗,2019,30(11):1822-1823.[12]严巨明,黄世华,石希均,等.氯雷他定联合甲基强的松冲击治疗小儿过敏性紫癜的临床疗效[J].现代生物医学进展,2016,16(17):3345-3347.[13]于宗丽.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效探究[J].中国处方药,2019,17(4):80-81.[14]吴封平,向明,曹宁丽.孟鲁司特钠治疗小儿过敏性紫癜的效果观察[J].药品评价,2021,18(7):435-437.[15]陈小凡.孟鲁司特钠联合氯雷他定治疗32例过敏性紫癜患儿的疗效[J].上海医药,2017,38(3):31-34.[16]朱淑华.两种药物联合应用方案治疗小儿过敏性紫癜的临床评价[J].中国继续医学教育,2018,10(4):117-119.[17]Bai LP,Yu J,Sun YX,et al.Efficacy of montelukast for the treatment of pediatric allergic purpura[J].Medicine,2019,98(39):e17239.

相似文献/References:

[1]李波.孟鲁司特钠联合酮替芬治疗小儿支气管炎的临床效果分析[J].医学信息官方网站,2018,31(02):130.[doi:10.3969/j.issn.1006-1959.2018.02.048]
 LI Bo.Clinical Analysis of Montelukast Sodium Combined With Ketotifen in the Treatment of Bronchitis in Children[J].Medical Information,2018,31(15):130.[doi:10.3969/j.issn.1006-1959.2018.02.048]
[2]尹静华.孟鲁司特钠治疗小儿哮喘的临床有效性分析[J].医学信息官方网站,2018,31(09):138.[doi:10.3969/j.issn.1006-1959.2018.09.043]
 YIN Jing-hua.Clinical Efficacy of Montelukast Sodium in Children with Asthma[J].Medical Information,2018,31(15):138.[doi:10.3969/j.issn.1006-1959.2018.09.043]
[3]张明荣.孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效分析[J].医学信息官方网站,2018,31(13):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
 ZHANG Ming-rong.Clinical Analysis of Montelukast Sodium Combined with Budesonide in the Treatment of Childhood Asthma[J].Medical Information,2018,31(15):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
[4]谢桃李,孙礼宾.血清25-羟维生素D在过敏性紫癜中的研究[J].医学信息官方网站,2019,32(09):116.[doi:10.3969/j.issn.1006-1959.2019.09.038]
 XIE Tao-li,SUN Li-bin.Study on Serum 25-hydroxyvitamin D in Henoch-Sch?觟nlein Purpura[J].Medical Information,2019,32(15):116.[doi:10.3969/j.issn.1006-1959.2019.09.038]
[5]关 楠.平凉市儿童过敏性紫癜相关环境因素调查研究[J].医学信息官方网站,2019,32(11):144.[doi:10.3969/j.issn.1006-1959.2019.11.042]
 GUAN Nan.Investigation on Environmental Factors Related to Children's Henoch-Schonlein Purpura in Pingliang City[J].Medical Information,2019,32(15):144.[doi:10.3969/j.issn.1006-1959.2019.11.042]
[6]冯晓阳,陆海涛,王 薇,等.溶菌酶肠溶片治疗过敏性紫癜的临床疗效[J].医学信息官方网站,2019,32(19):153.[doi:10.3969/j.issn.1006-1959.2019.19.050]
 FENG Xiao-yang,LU Hai-tao,WANG Wei,et al.Clinical Efficacy of Lysozyme Enteric-coated Tablets in the Treatment of Henoch-Schonlein Purpura[J].Medical Information,2019,32(15):153.[doi:10.3969/j.issn.1006-1959.2019.19.050]
[7]韦春峥,莫 彬,莫善圆,等.孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果[J].医学信息官方网站,2019,32(20):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
 WEI Chun-zheng,MO Bin,MO Shan-yuan,et al.Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis[J].Medical Information,2019,32(15):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
[8]甘 瀛.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效[J].医学信息官方网站,2019,32(12):150.[doi:10.3969/j.issn.1006-1959.2019.12.049]
 GAN Ying.Efficacy of Montelukast Sodium Combined with Budesonide in the Treatment of Cough Variant Asthma in Children[J].Medical Information,2019,32(15):150.[doi:10.3969/j.issn.1006-1959.2019.12.049]
[9]凌春艳.布地奈德气雾剂联合孟鲁司特钠治疗老年咳嗽变异性哮喘的疗效[J].医学信息官方网站,2020,33(07):144.[doi:10.3969/j.issn.1006-1959.2020.07.046]
 LING Chun-yan.Efficacy of Budesonide Aerosol Combined with Montelukast Sodium in the Treatment of Elderly Cough Variant Asthma[J].Medical Information,2020,33(15):144.[doi:10.3969/j.issn.1006-1959.2020.07.046]
[10]竺 琴,罗 军,向金波.儿童紫癜性肾炎的免疫机制研究[J].医学信息官方网站,2020,33(17):50.[doi:10.3969/j.issn.1006-1959.2020.17.015]
 ZHU Qin,LUO Jun,XIANG Jin-bo.Study on the Immune Mechanism of Children’s Purpuric Nephritis[J].Medical Information,2020,33(15):50.[doi:10.3969/j.issn.1006-1959.2020.17.015]

更新日期/Last Update: 1900-01-01